PT - JOURNAL ARTICLE AU - MIOKO MATSUO AU - RYUJI YASUMATSU AU - MUNEYUKI MASUDA AU - SATOSHI TOH AU - TAKAHIRO WAKASAKI AU - KAZUKI HASHIMOTO AU - RINA JIROMARU AU - TOMOMI MANAKO AU - TAKASHI NAKAGAWA TI - Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy AID - 10.21873/invivo.12780 DP - 2022 Mar 01 TA - In Vivo PG - 907--917 VI - 36 IP - 2 4099 - http://iv.iiarjournals.org/content/36/2/907.short 4100 - http://iv.iiarjournals.org/content/36/2/907.full SO - In Vivo2022 Mar 01; 36 AB - Background/Aim: The inflammation-based prognostic score (IBPS) has attracted attention recently as a prognostic biomarker for head and neck cancer patients. However, as the IBPS often changes after anticancer drug therapy, its independent prognostic value remains controversial. We aimed to investigate the relationship between the IBPS and prognosis in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC) treated with nivolumab, and investigate changes in the IBPS before and after nivolumab treatment. Patients and Methods: Total of 164 patients with RMHNSCC received nivolumab therapy were retrospectively analyzed. Results: Univariate analysis among the 164 patients revealed that the performance status (PS), immune-related adverse event (irAE) status, pre- and post-therapy Glasgow Prognostic Score (GPS), neutrophil-to-lymphocyte ratio (NLR), C-reactive protein-to-albumin ratio (CAR), platelet-to-lymphocyte ratio (PLR), and post-eosinophil count, were all significant predictors of overall survival (OS) (p<0.05). A multivariate analysis revealed that PS, irAEs, post-GPS, post-NLR, post-CAR, and post-eosinophil count were independent prognostic factors for overall survival. Conclusion: Post-treatment factors were identified as independent prognostic factors for RMHNSCC and can more accurately predict prognosis compared to nivolumab-treated RMHNSCC pre-treatment factors.